Three trade events in April 2026 have shifted the math for U.S. manufacturers evaluating where to produce. Each one independently changes the risk profile of existing production locations. Together they point in the same direction.
1. Pharmaceutical and Medical Device Tariffs Are Coming
On April 2, the Trump administration signed a Section 232 proclamation imposing a 100% tariff on patented pharmaceutical imports, effective July 31, 2026 for large companies and September 29, 2026 for smaller manufacturers. Medical devices and consumables are under active Section 232 investigation with additional tariffs expected.
For manufacturers producing in China, India, or other non-exempt countries, the exposure is significant. The proclamation’s preferential list includes the EU, Japan, South Korea, Switzerland, and the UK — not most of the low-cost manufacturing markets U.S. companies have relied on.
What it does not touch: goods produced under CAFTA-DR. Dominican Republic free zones export $2.6 billion in medical devices annually, representing 31% of total free zone exports. That production enters the U.S. duty-free and is not subject to the Section 232 structure. For medical device companies currently producing in tariff-exposed markets, the window to evaluate alternative production locations is narrowing. The July 31 effective date is 14 weeks away.
2. USMCA Faces Its First Formal Review on July 1
The 2026 USMCA joint review officially begins July 1. Three outcomes are possible: full extension, renegotiation with revisions, or a decline that triggers annual reviews and a 10-year sunset. Mexico’s government has made preservation a priority, but the outcome is not guaranteed.
For manufacturers operating in Mexico under USMCA duty-free status, this introduces a planning horizon question that did not exist 12 months ago. USMCA-qualifying goods are currently exempt from the 10% Section 122 tariff that replaced the struck-down IEEPA duties. That exemption is treaty-dependent.
CAFTA-DR has no equivalent review scheduled. The agreement has been in force since 2007 and has not been subject to renegotiation pressure in the current trade environment.
3. DR Expands Its Free Zone Footprint
On April 17, President Abinader inaugurated the Renacer Plant in the Quisqueya Free Zone in San Pedro de Macoris — the first food-grade recycled PET resin facility in the Caribbean. The plant represents DR free zone expansion into sustainable materials manufacturing, a category receiving significant capital interest from U.S. consumer goods brands managing ESG commitments alongside tariff exposure.
The DR free zone sector generated $8.6 billion in exports in 2025. Medical devices, apparel, footwear, and now sustainable materials are expanding the sector’s footprint beyond its traditional categories.
What This Means for Manufacturers Evaluating Location Decisions Now
The three developments point in the same direction. Tariff exposure is increasing on production in non-treaty markets. The most stable duty-free lane into the U.S. for manufactured goods is currently CAFTA-DR, and Dominican Republic free zones represent the largest and most developed production base within that corridor — the Caribbean Economic Corridor connecting East Coast U.S. markets to established Caribbean Basin manufacturing.
Setup timeline from decision to first production run runs 9 to 14 months. For companies facing July 31 pharma tariff exposure, that timeline means the evaluation needs to start now, not after the tariffs land.
Is your product category affected by the July 31 tariff deadline? Get a free analysis from EGS
Not sure if this applies to your company?
Get a free analysis of your expansion into the U.S. through Dominican Republic manufacturing — costs, free zones, tax benefits, and setup strategy.